564 related articles for article (PubMed ID: 20564408)
61. Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity.
Ardavanis A; Koumna S; Fragos I; Malliou S; Kyriakou F; Mantzaris I; Scorilas A; Rigatos G
Anticancer Res; 2008; 28(4C):2409-15. PubMed ID: 18751427
[TBL] [Abstract][Full Text] [Related]
62. Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
Stinchcombe TE; Socinski MA
Oncologist; 2008 Sep; 13(9):933-44. PubMed ID: 18784157
[TBL] [Abstract][Full Text] [Related]
63. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
[TBL] [Abstract][Full Text] [Related]
64. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
[TBL] [Abstract][Full Text] [Related]
65. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Wheatley-Price P; Ding K; Seymour L; Clark GM; Shepherd FA
J Clin Oncol; 2008 May; 26(14):2350-7. PubMed ID: 18467727
[TBL] [Abstract][Full Text] [Related]
66. Efficacy vs. effectiveness: erlotinib in previously treated non-small-cell lung cancer.
Sheikh N; Chambers CR
J Oncol Pharm Pract; 2013 Sep; 19(3):228-36. PubMed ID: 23175450
[TBL] [Abstract][Full Text] [Related]
67. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
[TBL] [Abstract][Full Text] [Related]
68. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
69. [How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].
Tang C; Li X; Guo W; Li J; Qin H; Wang W; Qu L; An J; Gao H; Liu X
Zhongguo Fei Ai Za Zhi; 2013 Jul; 16(7):345-52. PubMed ID: 23866664
[TBL] [Abstract][Full Text] [Related]
70. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.
Crinò L; Cappuzzo F; Zatloukal P; Reck M; Pesek M; Thompson JC; Ford HE; Hirsch FR; Varella-Garcia M; Ghiorghiu S; Duffield EL; Armour AA; Speake G; Cullen M
J Clin Oncol; 2008 Sep; 26(26):4253-60. PubMed ID: 18779612
[TBL] [Abstract][Full Text] [Related]
71. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
[TBL] [Abstract][Full Text] [Related]
72. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
Maruyama R; Nishiwaki Y; Tamura T; Yamamoto N; Tsuboi M; Nakagawa K; Shinkai T; Negoro S; Imamura F; Eguchi K; Takeda K; Inoue A; Tomii K; Harada M; Masuda N; Jiang H; Itoh Y; Ichinose Y; Saijo N; Fukuoka M
J Clin Oncol; 2008 Sep; 26(26):4244-52. PubMed ID: 18779611
[TBL] [Abstract][Full Text] [Related]
73. The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.
Krawczyk P; Kowalski DM; Wojas-Krawczyk K; Mlak R; Jaśkiewicz P; Kucharczyk T; Winiarczyk K; Krzakowski M; Milanowski J
Chemotherapy; 2012; 58(1):60-9. PubMed ID: 22338650
[TBL] [Abstract][Full Text] [Related]
74. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.
Faehling M; Eckert R; Kamp T; Kuom S; Griese U; Sträter J; Ott G; Spengler W
Lung Cancer; 2013 Jun; 80(3):306-12. PubMed ID: 23489557
[TBL] [Abstract][Full Text] [Related]
75. Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials.
Petrelli F; Borgonovo K; Cabiddu M; Barni S
Anticancer Drugs; 2011 Nov; 22(10):1010-9. PubMed ID: 21970852
[TBL] [Abstract][Full Text] [Related]
76. Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.
Boyer M; Horwood K; Pavlakis N; De Souza P; Millward M; Stein B; Johnston M; Abell F; Rischin D
Asia Pac J Clin Oncol; 2012 Sep; 8(3):248-54. PubMed ID: 22898114
[TBL] [Abstract][Full Text] [Related]
77. Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer.
Segawa Y; Hotta K; Umemura S; Fujiwara Y; Shinkai T; Ueoka H; Takigawa N; Tabata M; Kiura K; Tanimoto M
Cancer; 2006 Oct; 107(8):1866-72. PubMed ID: 16967452
[TBL] [Abstract][Full Text] [Related]
78. Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
Liam CK; Pang YK; Leow CH
Respirology; 2006 May; 11(3):287-91. PubMed ID: 16635086
[TBL] [Abstract][Full Text] [Related]
79. Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ
Complement Ther Med; 2014 Dec; 22(6):1010-8. PubMed ID: 25453521
[TBL] [Abstract][Full Text] [Related]
80. [Efficacy and safety of erlotinib as monotherapy for advanced non-small cell lung cancer].
Wang MZ; Zhang XT; Zhang XY; Zhang L; Zhong W; Xu LY; Li LY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Apr; 32(2):151-6. PubMed ID: 20450543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]